T Cell Response to Asparaginase in Leukemia Treatment
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This research study examines how your immune system (specifically T cells) reacts to asparaginase, a drug used to treat acute lymphoblastic leukemia. By understanding these reactions, doctors hope to predict and prevent allergic or sensitivity problems during your cancer treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with acute lymphoblastic leukemia (ALL), a blood cancer in early-stage lymphoid cells
- Your treatment plan includes asparaginase (a protein-based chemotherapy drug)
- You are at least 1 year old
- You are enrolled in the study before your consolidation phase (the second main phase of leukemia treatment)
- You have not had a bone marrow or stem cell transplant before
- You do not have Down syndrome (trisomy 21)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how the immune system reacts to a chemotherapy drug called PEG asparaginase in children and young adults. Understanding this could help improve treatment for leukemia by managing or reducing allergic reactions.
This trial looks at the side effects of the drug asparaginase in children and young adults with certain types of leukemia or lymphoma. It aims to better understand and manage these side effects to improve treatment safety.
This trial tests a combination of chemotherapy drugs (DA-EPOCH) with or without rituximab, plus a special form of the enzyme asparaginase (JZP458), for adults with newly diagnosed B-ALL or T-ALL. It aims to offer an effective option for those who cannot have standard pediatric-style treatment, such as older adults.
This trial tests adding an asparaginase drug to standard chemotherapy for adults with newly diagnosed acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma (LBL). The goal is to see if this combination improves outcomes.
This study looks at why some people develop liver problems while taking asparaginase, a common medicine used to treat newly diagnosed acute lymphoblastic leukemia (ALL). The goal is to use genetic information to better understand and potentially prevent this side effect.
This study looks at how many children develop high ammonia levels after receiving a cancer medicine called recombinant Erwinia asparaginase. It helps doctors understand side effects and keep patients safe.
Hear when a new Acute Lymphoblastic Leukemia ALL trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.